Home - Precision BioSciences At Precision BioSciences we are using our novel ARCUS genome editing technology to develop a new class of medicines designed to overcome and potentially cure, hard-to-treat conditions including rare genetic diseases ARCUS is a novel and proprietary genome editing platform discovered and developed by scientists at Precision BioSciences
Who We Are - Precision BioSciences That heritage lives and thrives today in Elo Life Systems, an independent company focused on food and agriculture Precision BioSciences completed the spin-out of Elo in December 2021 At the time, gene editing as a clinical intervention to treat – let alone cure – diseases was practically science fiction
Careers - Precision BioSciences Diversity and Inclusion Precision BioSciences is a company and a community dedicated to improving life This isn’t just a statement supporting the products that we’re developing – it is our collective desire to do our part in improving the lives of those around us Through a newly launched Diversity and Inclusion initiative, we are actively fostering an environment that attracts the best
ARCUS Genome Editing - Precision BioSciences ARCUS Genome Editing ARCUS is a proprietary genome editing technology discovered by scientists at Precision BioSciences ARCUS is based on a naturally occurring genome editing enzyme, I-CreI, that evolved in the algae Chlamydomonas reinhardtii to make highly specific cuts and DNA insertions in cellular DNA
Our Team - Precision BioSciences Our team includes pioneers in genome editing and leaders in cell and gene therapy who are committed to solving significant medical problems
News - Precision BioSciences Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference April 8, 2026 Investor RSS News DURHAM, N C -- (BUSINESS WIRE)--Apr 8, 2026-- Precision BioSciences, Inc (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo…
PRECISION BIOSCIENCES ARCUS Gene Editing A, thereby requiring lifelong treatment Precision BioSciences’ gene-editing approach is designed to use an ARCUS nuclease to delete persistent cccDNA and i n 80% reducion in e o chronic immune dysfuncion in patients Sustained loss of HBsAg is considered an important clinical endpoint for HBV therapies and therefore a key p
Precision BioSciences Provides Update on Allogeneic CAR T Programs and . . . About Precision BioSciences, Inc Precision BioSciences, Inc is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind